2017
DOI: 10.1111/apt.14105
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Linked ContentThis article is linked to Aksan et al papers. To view these articles visit https://doi.org/10.1111/apt.14126 and https://doi.org/10.1111/apt.14043.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
7
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(7 citation statements)
references
References 10 publications
(9 reference statements)
0
7
0
Order By: Relevance
“…The NMA used to inform the efficacy inputs of the present analysis has a number of limitations, which have been discussed previously, in both the original publication and in subsequent correspondence with the journal, including study design heterogeneity within the included trials, variation in patient characteristics, differences in iron dosing, and only five trials being included. 20 , 32–35 Since all economic evaluations are dependent on the input data, factors affecting the reliability of the results of the NMA also affect the present analysis. The systematic review conducted by Aksan et al additionally extracted data on adverse events occurring in patients with IBD and IDA receiving iron supplementation therapy.…”
Section: Discussionmentioning
confidence: 99%
“…The NMA used to inform the efficacy inputs of the present analysis has a number of limitations, which have been discussed previously, in both the original publication and in subsequent correspondence with the journal, including study design heterogeneity within the included trials, variation in patient characteristics, differences in iron dosing, and only five trials being included. 20 , 32–35 Since all economic evaluations are dependent on the input data, factors affecting the reliability of the results of the NMA also affect the present analysis. The systematic review conducted by Aksan et al additionally extracted data on adverse events occurring in patients with IBD and IDA receiving iron supplementation therapy.…”
Section: Discussionmentioning
confidence: 99%
“…FCM and IIM were also compared in two identically designed, open-label RCTs with a prespecified pooled analysis, but in 68.5% of enrolled patients the cause of IDA was a gynecological condition, rather than IBD as is of interest in the present analysis [20]. The limitations of the NMA used to inform the present analyses have been discussed by the authors of the NMA in the original publications and in post-publication correspondence [27,[41][42][43][44]. Despite its limitations, the NMA published by Aksan et al represents the best available evidence source on differences in clinical outcomes in patients with IDA and IBD receiving IV iron therapy.…”
Section: Discussionmentioning
confidence: 99%
“…We did not distinguish between ferric carboxymaltose and iron polymaltose in our analysis, as studies show no differences between preparations in response to treatment. 17,18 Ferric carboxymaltose is an appealing option (particularly for outpatient and community services) given its favourable side effect profile and rapid delivery. The data-sheet advises doses of 1.5-2 g for most patients, but with a maximum weekly dose of 1 g, two infusions would be required.…”
Section: Discussionmentioning
confidence: 99%
“…We did not distinguish between ferric carboxymaltose and iron polymaltose in our analysis, as studies show no differences between preparations in response to treatment 17,18 …”
Section: Discussionmentioning
confidence: 99%